ClinicalTrials.gg
RecruitingNCT06090890Updated Aug 8, 2025

Anti-inflammatory Therapy for Recurrent In-stent Restenosis

A Phase 4 interventional study of Colchicine and Prednisone in In-stent Restenosis, sponsored by Fu Wai Hospital, Beijing, China. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Fu Wai Hospital, Beijing, China · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).

Read the detailed description

This is a prospective, randomized, open-label, blinded-endpoint evaluation, single-center Study. A total of 252 RISR patients are planned to be enrolled in Fuwai Hospital, China. Then those included subjects will be randomized to standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group). The primary endpoint of the current study is target lesion ISR confirmed by coronary angiography for 12 months, and the secondary endpoint is Major adverse cardiovascular events (MACE: a composite of death, non-fatal myocardial infarction, non-fatal stroke, and target vascular revascularization) and each MACE component, target lesion revascularization, or other coronary artery disease revascularization for 12 months. The safety endpoint is adverse reactions to colchicine, adverse reactions of prednisone, or discontinued medication due to adverse reactions. In summary, the present study is to provide new evidence and strategy about anti-inflammatory therapy for recurrent In-stent restenosis after coronary intervention.

02

Conditions studied

  • In-stent Restenosis

Keywords

  • Anti-inflammatory therapy
  • In-stent Restenosis
  • Colchicine
  • Prednisone
03

In context

Lead sponsor

Fu Wai Hospital, Beijing, China is the lead sponsor of 13 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CAD patients over 18 years old;
  2. At least one coronary artery lesion meets the RISR criteria: target lesion ≥ 2 ISRs (stenosis of lumen diameter within the stent segment and within 5mm near and far of the stent ≥ 50%);
  3. Intended intervention treatment for RISR lesions;
  4. Acceptable for standard secondary prevention drug therapy for coronary heart disease, including dual antiplatelet therapy (DAPT) and statins;
  5. Willing to participate in the trial and complete follow-up, signing an form approved by the ethics committee

Exclusion criteria

Exclusion Criteria:

  1. The previous interventional treatment situation is unknown;
  2. The mechanism of intracavitary imaging to clarify ISR is operator-related (poor stent adhesion, incomplete dilation, and stent fracture);
  3. Clearly diagnose vascular inflammatory diseases or connective tissue diseases (including arteritis, Behcet's disease, systemic lupus erythematosus, etc.) involving the coronary artery;
  4. drugs, including , have been used in the past 30 days;
  5. There are to the use of prednisone or colchicine, including: serious infectious diseases, including active infection, , or AIDS patients; Hematological diseases, such as thrombocytopenia, severe anemia, leukemia, etc; Uncontrolled diabetes; Severe liver and kidney function damage; Active peptic ulcer or gastrointestinal bleeding; Severe osteoporosis (with previous pathological fractures); Inflammatory bowel disease or chronic diarrhea;
  6. A history of malignant tumors within 3 years;
  7. Cognitive impairment;
  8. Not willing to participate or follow up
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Active comparator
    control group

    DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary)

    Drug: Aspirin · Drug: P2Y12 Receptor Antagonist · Drug: Lipid-lowering drug

  • Experimental
    Colchicine group

    DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary) + Colchicine (0.5mg QD, orally)

    Drug: Colchicine · Drug: Aspirin · Drug: P2Y12 Receptor Antagonist · Drug: Lipid-lowering drug

  • Experimental
    Prednisone group

    DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary) + Prednisone (0.5mg/kg QD, orally)

    Drug: Prednisone · Drug: Aspirin · Drug: P2Y12 Receptor Antagonist · Drug: Lipid-lowering drug

Interventions

  • Add 0.5mg QD orally and start using it within 48 hours after intervention.

  • 0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.

  • Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.

    Also known as: Acetylsalicylic Acid

  • DrugP2Y12 inhibitorsStudies of P2Y12 inhibitorsP2Y12 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.

  • DrugLipid-lowering drug

    Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.

06

What researchers measure

Primary outcomes

  1. target lesion ISR

    target lesion ISR confirmed by coronary angiography for 12 months

    Time frame: 12 months after randomization

Secondary outcomes

  1. Major Adverse Cardiovascular Events

    a composite of mortality, non-fatal myocardial infarction, non-fatal stroke and target vascular revascularization

    Time frame: 12 months after randomization

  2. target lesion revascularization

    incidence of revascularization due to target lesion

    Time frame: 12 months after randomization

  3. other coronary artery disease revascularization

    incidence of revascularization due to other coronary artery disease

    Time frame: 12 months after randomization

07

Study locations

3 of 4 sites recruiting
08

References and documents

Publications

  • Yu M, Jiang Y, Song Z, Wei ZY, Tan F, Liu X, Zhang X, Zhu F, Shi Y, Huang J, Yang WX, Qian HY. Anti-inflammatory therapy for recurrent in-stent restenosis (AI-ISR): study protocol for a prospective, randomised, open-label, multicentre clinical trial. BMJ Open. 2025 Oct 27;15(10):e092235. doi: 10.1136/bmjopen-2024-092235. PubMed 41145262 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data will be securely stored and will be available only upon reasonable request and with approval from the study investigators, in accordance with BMJ Open's data-sharing policy.

Supporting information: Study protocol, Statistical analysis plan

Access criteria: De-identified individual participant data will be available only upon reasonable request and with approval from the study investigators, in accordance with BMJ Open's data-sharing policy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Oct 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2023
First posted
Oct 19, 2023
StartActual
Oct 30, 2023
Primary completionEst.
Oct 29, 2026
CompletionEst.
Oct 29, 2027
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06090890
Lead sponsor
Fu Wai Hospital, Beijing, China
Responsible party
Qian Haiyan (Director,Clinical Professor, Fu Wai Hospital, Beijing, China) — Principal investigator
First posted
Oct 19, 2023
Start date
Oct 30, 2023
Primary completion
Oct 29, 2026 (estimated)
Completion
Oct 29, 2027 (estimated)
Last update
Aug 8, 2025

Study contacts

Haiyan Qian
Contact
ahqhy712@163.com
+8613811386143
Zhiyao Wei
Contact
weizhiyaoyx@163.com
+8615521192379
Haiyan Qian
principal investigator · Fuwai Hospital, Beijing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Colchicine · Prednisone

Start the discussion